Expression and clinical significance of CyPJ in colorectal carcinoma

doi:10.3877/cma.j.issn.2095-3224.2017.05.007

Abstract

Abstract:

Objective

To investigate the expression and distribution of CyPJ in the colorectal cancer (CRC) and to explore its clinical significance in the development and progression of CRC.

Methods

The clinical data and surgical specimens of 61 patients with colorectal carcinoma who were treated from May 2015 to April 2016 that were collected from the Department of Gastrointestinal Surgery, Qingdao University Affiliated Yantai Yuhuangding Hospital. Detected by immunohistochemical staining technique in 61 cases of CyPJ protein expression in colorectal carcinoma and paracarcinoma tissues levels. The relationship of the expression of CyPJ with the clinicopathological features of colorectal carcinoma was analyzed using SPSS 23. 0 statistical analysis software. The count data were evaluated using the chi-square test and Fisher exact probability. P<0. 05 was considered as significant difference.

Results

Expression of CyPJ protein in colorectal cancer tissues is overexpressed and the positive expression of paracarcinoma tissues is visible, but the color lighter. Expression of CyPJ protein is mainly located in the cytoplasm, with little distribution in the nucleus. The positive expression rates of CyPJ protein in the CRC and paracarcinoma tissues were 78. 7% (48/61)and 39. 3% (24/61), respectively, with a significant difference (χ²=19. 520, P<0. 05). The expression of CyPJ protein in patients with CRC was however associated with the TNM stage, depth of tumor invasion and lymph node metastasis (χ²=13. 585, 11. 767, 13. 613, P<0. 05), but No significant correlation was found between the expression of CyPJ and age, sex, tumor size, tumor site, tumor differentiation and distant metastasis (χ²=1. 010, 0. 061, 0. 119, 1. 130, 2. 646, 0. 416, P>0. 05).

Conclusion

CyPJ protein is overexpressed in colorectal carcinoma, suggests that it may be associated with the occurrence, development and metastasis of colorectal carcinoma.

Key words: Colorectal neoplasms, Development, Metastasis, Cyclophilin J

Hongbo Zhang, Jian Chen, Jinchen Hu, Xixun Wang, Rongbao Jia, Lixin Jiang. Expression and clinical significance of CyPJ in colorectal carcinoma[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(05): 387-391.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.05.007

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I05/387

Figures/Tables 3

References 24

[1]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA: a cancer journal for clinicians, 2015, 65(2):87-108.
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA: a cancer journal for clinicians, 2016, 66(2):115-132.
[3]	Schiene-Fischer C, Aumüller T, Fischer G. Peptide bond cis/trans isomerases: a biocatalysis perspective of conformational dynamics in proteins[M]. Molecular Chaperones. Springer, 2011, 328:35-67.
[4]	Handschumacher RE, Harding MW, Rice J, et al. Cyclophilin: a specific cytosolic binding protein for cyclosporin A[J]. Science, 1984, 226(4674):544-547.
[5]	Feng W, Xin Y, Xiao Y, et al. Cyclophilin A Enhances Cell Proliferation and Xenografted Tumor Growth of Early Gastric Cancer[J]. Digestive diseases and sciences, 2015, 60(9):2700-2711.
[6]	Zhang H, Chen J, Liu F, et al. CypA, a gene downstream of HIF-1alpha, promotes the development of PDAC[J]. PloS one, 2014, 9(3):e92824.
[7]	Peng Y, Li X, Wu M, et al. New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer[J]. Molecular BioSystems, 2012, 8(11):3077-3088.
[8]	Meng DQ, Li PL, Xie M. Expression and role of cyclophilin B in stomach cancer[J]. Genetics and molecular research : GMR, 2015, 14(2):5346-5354.
[9]	Jeong K, Kim H, Kim K, et al. Cyclophilin B is involved in p300-mediated degradation of CHOP in tumor cell adaptation to hypoxia[J]. Cell Death & Differentiation, 2014, 21(3):438-450.
[10]	Chen J, Liefke R, Jiang L, et al. Biochemical Features of Recombinant Human Cyclophilin J[J]. Anticancer research, 2016, 36(3):1175-1180.
[11]	Zhou Z, Ying K, Dai J, et al. Molecular cloning and characterization of a novel peptidylprolyl isomerase (cyclophilin)-like gene (PPIL3) from human fetal brain[J]. Cytogenetics and cell genetics, 2001, 92(3-4):231-236.
[12]	祁震宇，惠国桢，李瑶, 等. 脑胶质瘤相关的全长新基因PPIL-3的克隆和蛋白质特性的研究[J]. 中华神经外科杂志, 2009, 25(3):213-217.
[13]	Avila MA, Chen J, Chen S, et al. Cyclophilin J Is a Novel Peptidyl-Prolyl Isomerase and Target for Repressing the Growth of Hepatocellular Carcinoma[J]. PloS one, 2015, 10(5):e0127668.
[14]	Qi ZY, Hui GZ, Li Y, et al. cDNA microarray in isolation of novel differentially expressed genes related to human glioma and clone of a novel full-length gene[J]. Chinese medical journal, 2005, 118(10):799-805.
[15]	Pasquariello N, Catanzaro G, Marzano V, et al. Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis[J]. The Journal of biological chemistry, 2009, 284(43):29413-29426.
[16]	Wang J, Tai L S, Tzang CH, et al. 1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells[J]. Oncology reports, 2008, 19(5):1155-1164.
[17]	Camp NJ, Lin WY, Bigelow A, et al. Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus[J]. Cancer research, 2016, 76(7):1916-1925.
[18]	Selmansberger M, Feuchtinger A, Zurnadzhy L, et al. CLIP2 as radiation biomarker in papillary thyroid carcinoma[J]. Oncogene, 2015, 34(30):3917-3925.
[19]	Bendris N, Lemmers B, Blanchard JM. Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors[J]. Cell cycle, 2015, 14(12):1786-1798.
[20]	Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation[J]. Development, 2013, 140(15):3079-3093.
[21]	Rollano Penaloza OM, Lewandowska M, Stetefeld J, et al. Apoptins: selective anticancer agents[J]. Trends in molecular medicine, 2014, 20(9):519-528.
[22]	Huo DH, Yi LN, Yang J. Interaction with Ppil3 leads to the cytoplasmic localization of Apoptin in tumor cells[M]. Biochemical and biophysical research communications. 2008, 372(1):14-18.
[23]	Shou J, You L, Yao J, et al. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3[J]. Cancer letters, 2016, 379(1):124-133.
[24]	Chen S, Zhang M, Ma H, et al. Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance[J]. Cancer chemotherapy and pharmacology, 2008, 61(3):459-469.

分组	例数	CyPJ蛋白表达		阳性表达率（%）
分组	例数	阳性	阴性	阳性表达率（%）
癌组织	61	48	13	78.7
癌旁组织	61	24	37	39.3
χ²值				19.520
P值				<0.001

分组	例数	CyPJ蛋白表达		阳性表达率（%）
分组	例数	阳性	阴性	阳性表达率（%）
癌组织	61	48	13	78.7
癌旁组织	61	24	37	39.3
χ²值				19.520
P值				<0.001

临床病理特征		例数	CyPJ表达		χ²值	P值
临床病理特征		例数	阳性	阴性	χ²值	P值
性别					1.010	0.315
	男	30	22（73.3）	8（26.7）
	女	31	26（83.9）	5（16.1）
年龄					0.061	0.806
	>60岁	30	24（80.0）	6（20.0）
	≤60岁	31	24（77.4）	7（22.6）
肿瘤部位					1.130	0.288
	结肠	36	30（83.3）	6（16.7）
	直肠	25	18（72.0）	7（28.0）
肿瘤大小					0.119	0.730
	>5 cm	21	16（76.2）	5（23.8）
	≤5 cm	40	32（80.0）	8（20.0）
肿瘤分化程度					2.130	0.392^*
	高分化	12	10（83.3）	2（16.7）
	中分化	42	31（73.8）	11（26.2）
	低分化	7	7（100）	0（0）
TNM分期					13.585	<0.001
	Ⅰ~Ⅱ期	31	18（58.0）	13（42.0）
	Ⅲ~Ⅳ期	30	30（100%）	0（0）
肿瘤浸润深度					13.613	<0.001
	T1~2期	10	3（30.0）	7（70.0）
	T3~4期	51	45（88.2）	6（11.8）
淋巴结转移					11.767	<0.001
	N0期	33	20（60.6）	13（39.4）
	N1~2期	28	28（100）	0（0）
远处转移					0.416	0.519
	M0期	56	43（76.8）	13（23.2）
	M1期	5	5（100）	0（0）

临床病理特征		例数	CyPJ表达		χ²值	P值
临床病理特征		例数	阳性	阴性	χ²值	P值
性别					1.010	0.315
	男	30	22（73.3）	8（26.7）
	女	31	26（83.9）	5（16.1）
年龄					0.061	0.806
	>60岁	30	24（80.0）	6（20.0）
	≤60岁	31	24（77.4）	7（22.6）
肿瘤部位					1.130	0.288
	结肠	36	30（83.3）	6（16.7）
	直肠	25	18（72.0）	7（28.0）
肿瘤大小					0.119	0.730
	>5 cm	21	16（76.2）	5（23.8）
	≤5 cm	40	32（80.0）	8（20.0）
肿瘤分化程度					2.130	0.392^*
	高分化	12	10（83.3）	2（16.7）
	中分化	42	31（73.8）	11（26.2）
	低分化	7	7（100）	0（0）
TNM分期					13.585	<0.001
	Ⅰ~Ⅱ期	31	18（58.0）	13（42.0）
	Ⅲ~Ⅳ期	30	30（100%）	0（0）
肿瘤浸润深度					13.613	<0.001
	T1~2期	10	3（30.0）	7（70.0）
	T3~4期	51	45（88.2）	6（11.8）
淋巴结转移					11.767	<0.001
	N0期	33	20（60.6）	13（39.4）
	N1~2期	28	28（100）	0（0）
远处转移					0.416	0.519
	M0期	56	43（76.8）	13（23.2）
	M1期	5	5（100）	0（0）

Please choose a citation manager

Content to export